What We're Looking Forward to in Rheumatology in H2 2026
We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.
The second half of 2026 arrives with one of the most consequential regulatory and clinical calendars rheumatology has seen in years — and unlike many recent half-years defined primarily by conference readouts, H2 2026 carries genuine first-in-disease potential across multiple conditions simultaneously. The most closely watched near-term decision is tildrakizumab's October 29 PDUFA for psoriatic arthritis (PsA), which will land into a market already processing bimekizumab's BE BOLD superiority data over risankizumab and a freshly approved competitor in deucravacitinib — making it the most crowded and actively contested approval environment PsA has seen in a single calendar year.